Detalles de la búsqueda
1.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Oncology
; 102(3): 239-251, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37729889
2.
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Oncology
; 101(8): 491-501, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429266
3.
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
BMC Gastroenterol
; 23(1): 222, 2023 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37380950
4.
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.
BMC Gastroenterol
; 22(1): 275, 2022 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35655156
5.
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
BMC Gastroenterol
; 22(1): 535, 2022 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36550416
6.
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Oncology
; 99(8): 507-517, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33946070
7.
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Oncology
; 99(5): 327-335, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677453
8.
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Oncology
; 99(8): 491-498, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000725
9.
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
BMC Gastroenterol
; 21(1): 306, 2021 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34332532
10.
Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
J Gastroenterol Hepatol
; 36(6): 1685-1693, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33326154
11.
Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
Oncology
; 98(10): 727-733, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32712613
12.
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Oncology
; 98(11): 787-797, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32882687
13.
Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Hepatol Res
; 50(7): 885-888, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32088930
14.
Reply from the authors.
Hepatol Res
; 50(12): 1393, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33280200
15.
Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Eur J Gastroenterol Hepatol
; 35(9): 989-996, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395206
16.
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.
Cancers (Basel)
; 15(3)2023 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765804
17.
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Liver Cancer
; 12(3): 251-261, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601981
18.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Intern Med
; 62(12): 1771-1774, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328580
19.
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Cancers (Basel)
; 15(8)2023 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37190231
20.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Case Rep Gastroenterol
; 16(1): 110-115, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35431768